As for NAFLD, recent findings suggest that aberrant signaling of circRNA_0046367 and circRNA_0046366/miR-34a/PPAR may be involved in steatosis and could represent a therapeutic target in NAFLD therapy [21]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.